321 related articles for article (PubMed ID: 33305459)
1. Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study.
Di Gregorio M; Torri Clerici VLA; Fenu G; Gaetani L; Gallo A; Cavalla P; Ragonese P; Annovazzi P; Gajofatto A; Prosperini L; Landi D; Nicoletti CG; Di Carmine C; Totaro R; Nociti V; De Fino C; Ferraro D; Tomassini V; Tortorella C; Righini I; Amato MP; Manni A; Paolicelli D; Iaffaldano P; Lanzillo R; Moccia M; Buttari F; Fantozzi R; Cerqua R; Zagaglia S; Farina D; De Luca G; Buscarinu MC; Pinardi F; Cocco E; Gasperini C; Solaro CM; Di Filippo M
Eur J Neurol; 2021 Apr; 28(4):1299-1307. PubMed ID: 33305459
[TBL] [Abstract][Full Text] [Related]
2. Clinical and radiological characteristics and outcomes of patients with recurrent or relapsing tumefactive demyelination.
Pervin I; Ramanathan S; Cappelen-Smith C; Vucic S; Reddel SW; Hardy TA
Mult Scler Relat Disord; 2024 Feb; 82():105408. PubMed ID: 38219394
[TBL] [Abstract][Full Text] [Related]
3. Clinical and radiological characteristics of tumefactive demyelinating lesions: follow-up study.
Altintas A; Petek B; Isik N; Terzi M; Bolukbasi F; Tavsanli M; Saip S; Boz C; Aydin T; Arici-Duz O; Ozer F; Siva A
Mult Scler; 2012 Oct; 18(10):1448-53. PubMed ID: 22419670
[TBL] [Abstract][Full Text] [Related]
4. Occurrence and long-term outcome of tumefactive demyelinating lesions in multiple sclerosis.
Totaro R; Di Carmine C; Splendiani A; Torlone S; Patriarca L; Carrocci C; Sciamanna S; Marini C; Carolei A
Neurol Sci; 2016 Jul; 37(7):1113-7. PubMed ID: 27083895
[TBL] [Abstract][Full Text] [Related]
5. Tumefactive demyelinating lesions (TDLs): A case series of clinicoradiological features.
Jain RS; Khan I; Kandelwal K; Desai T
Clin Neurol Neurosurg; 2017 Nov; 162():91-94. PubMed ID: 28987645
[TBL] [Abstract][Full Text] [Related]
6. Proton magnetic resonance spectroscopy differentiates tumefactive demyelinating lesions from gliomas.
Ikeguchi R; Shimizu Y; Abe K; Shimizu S; Maruyama T; Nitta M; Abe K; Kawamata T; Kitagawa K
Mult Scler Relat Disord; 2018 Nov; 26():77-84. PubMed ID: 30237108
[TBL] [Abstract][Full Text] [Related]
7. Tumefactive demyelinating lesions: a retrospective cohort study in Thailand.
Ongphichetmetha T; Aungsumart S; Siritho S; Apiwattanakul M; Tanboon J; Rattanathamsakul N; Prayoonwiwat N; Jitprapaikulsan J
Sci Rep; 2024 Jan; 14(1):1426. PubMed ID: 38228919
[TBL] [Abstract][Full Text] [Related]
8. Central nervous system tumefactive demyelinating lesions: Risk factors of relapse and follow-up observations.
Li X; Miao X; Wang Y; Sun J; Gao H; Han J; Li Y; Wang Q; Sun C; Liu J
Front Immunol; 2022; 13():1052678. PubMed ID: 36532021
[TBL] [Abstract][Full Text] [Related]
9. Clinical and imaging correlation in patients with pathologically confirmed tumefactive demyelinating lesions.
Tremblay MA; Villanueva-Meyer JE; Cha S; Tihan T; Gelfand JM
J Neurol Sci; 2017 Oct; 381():83-87. PubMed ID: 28991721
[TBL] [Abstract][Full Text] [Related]
10. Tumefactive demyelinating lesions as a first clinical event: Clinical, imaging, and follow-up observations.
Jeong IH; Kim SH; Hyun JW; Joung A; Cho HJ; Kim HJ
J Neurol Sci; 2015 Nov; 358(1-2):118-24. PubMed ID: 26333950
[TBL] [Abstract][Full Text] [Related]
11. Population-based incidence and clinico-radiological characteristics of tumefactive demyelination in Olmsted County, Minnesota, United States.
Fereidan-Esfahani M; Decker PA; Eckel Passow JE; Lucchinetti CF; Flanagan EP; Tobin WO
Eur J Neurol; 2022 Mar; 29(3):782-789. PubMed ID: 34773343
[TBL] [Abstract][Full Text] [Related]
12. Performance of Apparent Diffusion Coefficient Values and Conventional MRI Features in Differentiating Tumefactive Demyelinating Lesions From Primary Brain Neoplasms.
Mabray MC; Cohen BA; Villanueva-Meyer JE; Valles FE; Barajas RF; Rubenstein JL; Cha S
AJR Am J Roentgenol; 2015 Nov; 205(5):1075-85. PubMed ID: 26496556
[TBL] [Abstract][Full Text] [Related]
13. Conversion of clinically isolated syndrome to multiple sclerosis: a prospective study.
Kolčava J; Kočica J; Hulová M; Dušek L; Horáková M; Keřkovský M; Stulík J; Dostál M; Kuhn M; Vlčková E; Bednařík J; Benešová Y
Mult Scler Relat Disord; 2020 Sep; 44():102262. PubMed ID: 32570179
[TBL] [Abstract][Full Text] [Related]
14. Tumefactive demyelinating lesions of 15 patients: Clinico-radiological features, management and review of the literature.
Sánchez P; Meca-Lallana V; Barbosa A; Manzanares R; Palmí I; Vivancos J
J Neurol Sci; 2017 Oct; 381():32-38. PubMed ID: 28991707
[TBL] [Abstract][Full Text] [Related]
15. Defining high, medium and low impact prognostic factors for developing multiple sclerosis.
Tintore M; Rovira À; Río J; Otero-Romero S; Arrambide G; Tur C; Comabella M; Nos C; Arévalo MJ; Negrotto L; Galán I; Vidal-Jordana A; Castilló J; Palavra F; Simon E; Mitjana R; Auger C; Sastre-Garriga J; Montalban X
Brain; 2015 Jul; 138(Pt 7):1863-74. PubMed ID: 25902415
[TBL] [Abstract][Full Text] [Related]
16. Mass lesions in the brain: tumor or multiple sclerosis? Clinical and imaging characteristics and course from a single reference center.
Kilic AK; Kurne AT; Oguz KK; Soylemezoglu F; Karabudak R
Turk Neurosurg; 2013; 23(6):728-35. PubMed ID: 24310455
[TBL] [Abstract][Full Text] [Related]
17. Characterization of tumefactive demyelinating lesions using MR imaging and in-vivo proton MR spectroscopy.
Malhotra HS; Jain KK; Agarwal A; Singh MK; Yadav SK; Husain M; Krishnani N; Gupta RK
Mult Scler; 2009 Feb; 15(2):193-203. PubMed ID: 19181773
[TBL] [Abstract][Full Text] [Related]
18. Tumefactive demyelinating lesions: A comprehensive review.
Algahtani H; Shirah B; Alassiri A
Mult Scler Relat Disord; 2017 May; 14():72-79. PubMed ID: 28619436
[TBL] [Abstract][Full Text] [Related]
19. Neuroimaging and clinicopathological differences between tumefactive demyelinating lesions and sentinel lesions of primary central nervous system lymphoma.
Sun C; Han J; Lin Y; Qi X; Li C; Liu J; Qiu F
Front Immunol; 2022; 13():986473. PubMed ID: 36059526
[TBL] [Abstract][Full Text] [Related]
20. Clinical and diagnostic features of patients with familial multiple sclerosis.
Andrijauskis D; Balnyte R; Keturkaite I; Vaitkus A
Med Hypotheses; 2019 Oct; 131():109310. PubMed ID: 31443766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]